Living with severe asthma can be a daily struggle, impacting your quality of life and overall well-being. Fortunately, medical advancements continue to offer hope to asthma sufferers, with Fasenra emerging as a breakthrough treatment for severe asthma. In this article, we will delve into what Fasenra is, how it works, and the benefits it provides for those living with this chronic condition.
Fasenra is a medication specifically designed for patients aged 12 years and older with severe eosinophilic asthma. It belongs to a class of medications known as monoclonal antibodies and is administered through subcutaneous injections. Fasenra works by targeting and reducing the levels of eosinophils, a type of white blood cell that plays a key role in allergic asthma.
Fasenra contains an active ingredient called benralizumab, which binds to a protein known as the interleukin-5 receptor alpha. This interaction inhibits the signalling pathway responsible for eosinophil activation and survival, leading to a reduction in eosinophil levels. By controlling eosinophilic inflammation, Fasenra helps reduce asthma exacerbations and improve lung function, enabling patients to regain control over their condition.
Fasenra offers several benefits for individuals living with severe asthma. Firstly, clinical studies have shown that Fasenra significantly reduces the rate of asthma exacerbations, leading to fewer hospitalizations and emergency room visits. This reduction in exacerbations translates into improved symptom control and a better overall quality of life.
Secondly, Fasenra has demonstrated its ability to enhance lung function. By reducing eosinophil levels, Fasenra helps decrease airway inflammation and improve lung function, allowing patients to breathe more easily. This improvement in lung function enables individuals to engage in daily activities without the constant fear of asthma attacks or shortness of breath.
Moreover, Fasenra has been shown to reduce the need for oral corticosteroids, which are commonly used to manage severe asthma. Long-term use of oral corticosteroids can lead to various side effects, including weight gain, mood swings, and osteoporosis. By reducing the dependency on these medications, Fasenra minimizes the risk of such side effects and promotes healthier long-term asthma management.
While Fasenra offers remarkable benefits, it is important to note some considerations before starting this treatment. Firstly, Fasenra is not suitable for individuals with non-eosinophilic asthma, as it specifically targets eosinophilic inflammation. Therefore, proper diagnosis and identification of eosinophilic asthma are essential before considering Fasenra.
Additionally, Fasenra requires regular subcutaneous injections, typically administered every 4 to 8 weeks, as prescribed by a healthcare professional. Adhering to the recommended treatment schedule is crucial for optimal results. It is essential to work closely with your healthcare provider to ensure proper administration and monitor the effectiveness of Fasenra.
Fasenra represents a significant breakthrough in the treatment of severe eosinophilic asthma. By targeting eosinophils and reducing inflammation, Fasenra provides relief from asthma symptoms, improves lung function, and reduces the risk of exacerbations. However, it is essential to consult with your healthcare provider to determine if Fasenra is the right treatment option for your specific condition. With the help of Fasenra, individuals with severe asthma can regain control over their lives and experience a better quality of life.
©2022 by Laudee Group